Recent Updates
Recently added Catalysts
ORIC

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Key Takeaway: SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., c
Price reaction · baseline $16.1 (2022-01-03 close) · hit after-hours · clean, no other ORIC news in the window
day 0 close · peak
-1.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
10.1%
average across 6 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
ORIC-944
Phase 1 · Metastatic Prostate Cancer

Full Press Release Details

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:00 p.m. ET.
A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 30 days following the event.
About ORIC Pharmaceuticals, Inc.
Last updated: Jan 4, 2022